Literature DB >> 2382901

Increased levels of interleukin-1 in bronchoalveolar washings from children with bacterial pulmonary infections.

R W Wilmott1, J T Kassab, P L Kilian, W R Benjamin, S D Douglas, R E Wood.   

Abstract

To investigate its role in pulmonary infections, concentrations of interleukin-1 were measured in 22 bronchoalveolar lavage fluid (BALF) samples from 19 children with cystic fibrosis (CF), and in 13 disease controls by enzyme-linked immunosorbent assay (ELISA) for IL-1 beta and the D10.G4.1 proliferation assay for IL-1 activity. Significantly higher levels of IL-1 beta and IL-1 activity were found in BALF from patients with bacterial pulmonary infections than in those without such infection. There was no significant difference between the levels in patients with CF and pulmonary infections and those in children with bacterial infections complicating other diseases. High performance liquid chromatography showed that most of the IL-1 beta was associated with a molecular weight peak of 17 to 18 kD. Pulmonary inflammation reflected by the number of polymorphonuclear leukocytes (PMN) in the sample correlated significantly with the IL-1 concentration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2382901     DOI: 10.1164/ajrccm/142.2.365

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  18 in total

1.  Inflammatory bronchopulmonary response of preterm infants with microbial colonisation of the airways at birth.

Authors:  P Groneck; B Goetze-Speer; C P Speer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-01       Impact factor: 5.747

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Comparison of cell profiles in separately evaluated fractions of bronchoalveolar lavage (BAL) fluid in children.

Authors:  P Pohunek; H Pokorná; I Stríz
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

4.  Corticosteroid treatment in cystic fibrosis.

Authors:  J F Price; P Greally
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

5.  Increased carbon monoxide in exhaled air of patients with cystic fibrosis.

Authors:  P Paredi; P L Shah; P Montuschi; P Sullivan; M E Hodson; S A Kharitonov; P J Barnes
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

Review 6.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

7.  Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1 alpha.

Authors:  A Buret; M L Dunkley; G Pang; R L Clancy; A W Cripps
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

8.  Production of beta-defensins by human airway epithelia.

Authors:  P K Singh; H P Jia; K Wiles; J Hesselberth; L Liu; B A Conway; E P Greenberg; E V Valore; M J Welsh; T Ganz; B F Tack; P B McCray
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

9.  Production of granulocyte-macrophage colony-stimulating factor by cultured human tracheal epithelial cells.

Authors:  L Churchill; B Friedman; R P Schleimer; D Proud
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

10.  Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases.

Authors:  K Oishi; F Sonoda; S Kobayashi; A Iwagaki; T Nagatake; K Matsushima; K Matsumoto
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.